5-ASA


Also found in: Dictionary, Medical.
AcronymDefinition
5-ASA5-Aminosalicylic Acid (anti-inflammatory drug)
References in periodicals archive ?
Treatment with 5-ASA and CHCR prevented this target from modulating the progression of colitis (table 2).
Effect of Cyperus rotundus on cytokine gene expression in experimental inflammatory bowel disease
Compounds based on premix alone, premix with 5-ASA, premix with 6 wt% of halloysites and premix with 5-ASA encapsulated HNT were then processed in a twin-screw extruder (Haake Rheomex PTW 16 OS, Thermo Scientific, Germany) at a screw speed of 60 rpm.
Melt-blended halloysite nanotubes/wheat starch nanocomposites as drug delivery system
Although 5-ASA is commonly imputed as a cause, 9 reported patients were not on 5-ASA therapy, and these cases mostly occurred during flare up of the bowel disease (Table).
Granulomatous Interstitial Nephritis as a Manifestation of Crohn Disease
6) Traditionally 5-ASAs have been given as multiple doses 2 - 3 times daily, resulting in poor patient compliance.
Disorders of the gastrointestinal tract are common and frequently prompt patients to seek medical care
The addition of antibiotics did not reduce the odds of a disease flare in the children who started therapy with 5-ASA, suggesting that pediatric Crohn's patients can be managed with fewer medications.
5-ASA therapy can suppress Crohn's flares
Analysis of the 5-ASA Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
Research and Markets: Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Simultaneously, new data from the CONTRIBUTE trial showed that adding CORTIMENTAMMXA 9 mg was significantly more effective than placebo at inducing combined clinical and endoscopic remission in patients with ulcerative colitis experiencing a flare up despite oral 5-ASA therapy.
Switzerland : Ferring announces European launch of CORTIMENTAMMXA (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy
This randomised, double-blind, placebo-controlled Phase IIIb clinical study will evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Santarus Inc launches Phase IIIb trial of UCERIS as an add-on therapy in patients with mild or moderate active ulcerative colitis
Most patients (89%) reported that they would be interested in trying a once daily 5-ASA medication.
Ulcerative colitis: patients and physicians don't always agree
Two other agents in this class, balsalazide (Colazal) and olsalazine (Dipentum), are broken down in the colon to 5-ASA.
GI agents: Part II
In more serious cases, treatment with sulfasalazine, 5-ASA drugs, and corticosteroids may be required.
Letter to the editor
Patients with inactive UC and CD were treated with 5-ASA and 5-ASA plus the immunosuppressor azathioprine, respectively.
Antioxidant defense in erythrocytes and plasma of patients with active and quiescent Crohn disease and ulcerative colitis: a chemiluminescent study
Acronyms browser ?
Full browser ?